Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine + CHAG + chidamide for relapsed/refractory acute myeloid leukemia
ChiCTR1800020372Phase 4Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Dec 2018
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of decitabine, tucidinostat, aclarubicin, homoharringtonine, cytarabine and 1 more in acute myeloid leukemia (AML), sponsored by Henan Cancer Hospital. Primary endpoint: Objective response rate. Started Dec 2018; status: recruiting.
02
Drugs
decitabinetucidinostataclarubicinhomoharringtoninecytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR1800020372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020372.